CNSPCNS Pharmaceuticals, Inc.Running, no new patients
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme, Adult
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 252 (final count)
- Started
- May 18, 2021
- Main results expected
- Apr 27, 2026
- Fully finished
- Jul 15, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Through study completion an average of 4 years.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04762069 · record last updated 2026-04-15 · checked 2026-11-09 15:47 UTC